I hope Kevin stays for the long haul too. They have defimitely done a 180 on corporate communications, like total radio silence. My gut tells me they are trying to present themselves as a traditional pharmaceutical company and not a psychedelics company. On another board it was suggested their recent change in clinical trial language from "micro dose" to "low dose" is an attempt by MNMD to disassociate itself with the recreational psychedelics culture and align itself with pharmaceutical culture. It seems logical.
News 
Market Data 
Discover 
